<DOC>
	<DOCNO>NCT00211679</DOCNO>
	<brief_summary>The purpose study determine whether intra-articular injection botulinum toxin effective treatment chronic knee paindue arthritis .</brief_summary>
	<brief_title>Intra-articularInjection Botulinum Toxin Type</brief_title>
	<detailed_description>Chronic knee pain unresponsive oral medication intra-articular corticosteroid viscosupplements important treatment problem , especially young , old complex medical problem preclude joint reconstructive surgery . We hypothesize intra-articular botulinum toxin could provide important joint pain relief patient . This prospective , double blined , placebo control 6month trial open label extension phase pain return baseline level ( re-injection 100units botulinum toxin 6 month followup thereafter . Comparisons : Intra-articular injection bootulinum toxin type compare intra-articular injection lidocaine saline .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Male female subject , 18 year age old . Written informed consent write authorization use release health research study information obtain . Subject chronic Knee pain 1 year . Subject pain &gt; 4.5 numerical rating scale 0 10 . Ability follow study instruction likely complete require visit . Negative urine pregnancy test day treatment prior administration study medication ( female childbearing potential applicable ) Patients previously treat intraarticular corticosteroid viscosupplementation injection . Patients rheumatoid arthritis must fail therapy standard DMARDs ( disease modify antirheumatic drug ) antiTNF agent unless contraindication TNF blocker . Patients consider candidate Knee joint replacement young age , abnormality periarticular tissue comorbid condition . Must ambulatory able perform sit stand . Use aminoglycoside antibiotic , curarelike agent , agent might interfere neuromuscular function . Any medical condition may put subject increase risk exposure botulinum neurotoxin include diagnose myasthenia gravis , EatonLambert syndrome , amytrophic lateral sclerosis , disorder might interfere neuromuscular function presence severe peripheral neuropathy . Females pregnant , breastfeeding , plan pregnancy study think may pregnant start study , female childbearing potential unable unwilling use reliable form contraception study . Known allergy sensitivity component study medication . Evidence recent alcohol drug abuse . Infection injection site systemic infection ( postpone study entry one week follow recovery . Known , uncontrolled serious systemic disease and/or life expectancy le 12 month . Concurrent participation another investigational drug device study participation 30 day immediately prior study enrollment . Any condition situation , investigator 's opinion , may put subject significant risk , confound study result , interfere significantly subject 's participation study . Patients whose pain rat less 4.5 10 point Numerical Pain Rating scale screen visit Patients coumadin heparin increase risk bleed joint Serious unstable psychiatric disease cognitive impairment would limit evaluation response treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>Joint pain</keyword>
	<keyword>Knee Pain</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Intra-articular Botulinum Toxin Type A</keyword>
</DOC>